Financials
Financial year 2025
Farmafyt from Chaudfontaine, company number BE0882541137, closed financial year 2025 with a result of € 19,750 after tax. For that financial year Farmafyt recorded a gross margin of € 272,654 and equity of € 552,961. Compared with financial year 2024, the result moved from € 36,670 to € 19,750. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 26, 2026.
€ 552,961
▲ 4% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 19,750
▼ 46% vs 2024
Profit after tax over the fiscal year.
€ 28,725
▼ 42% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 334,361.
People and assets in 2025
3
▲ 0.6 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 225,948
▲ 27% vs 2024
€ 75,300 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
€ 83,333
▲ 72% vs 2024
Loans from banks and other lenders, long and short.
€ 25,977
▼ 52% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 27,227
▲ 14% vs 2024
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 161,252 | € 197,799 | € 243,481 | € 272,654 | ▲ 12% |
| Profit after taxes | € -8,415 | € 40,498 | € 36,670 | € 19,750 | ▼ 46% |
| Equity | € 456,043 | € 496,541 | € 533,211 | € 552,961 | ▲ 4% |
| Total debts | € 171,116 | € 288,958 | € 126,089 | € 136,538 | ▲ 8% |
| Cash | € 54,001 | € 96,311 | € 49,777 | € 28,725 | ▼ 42% |
| Retained profit | € 237,443 | € 277,941 | € 314,611 | € 334,361 | ▲ 6% |
| Bank debt | € 20,398 | € 125,000 | € 48,333 | € 83,333 | ▲ 72% |
| Balance sheet total | € 627,159 | € 785,499 | € 659,301 | € 689,499 | ▲ 5% |
| Employees (FTE) | 2.1 | 2 | 2.4 | 3 | ▲ 0.6 |
Key figures of Farmafyt, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Farmafyt?
What happened at Farmafyt in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 19,750 (▼ 46% vs 2024). Source: NBB ↗
- New establishment in Chaudfontaine. KBO
- New establishment in Sint-Niklaas. KBO
- Start of the company according to the CBE. KBO
In short
From € 8,415 loss in 2022 to € 19,750 profit in 2025.
Paid € 42,041 in corporate taxes since 2022.
Best year ever: 2023, with € 40,498 profit.
On average € 90,900 of value added per employee in 2025.
A new publication or filing at Farmafyt? We notify you, reason included.
Follow FarmafytDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of FARMAFYT HEALTHCARE, NOSHAQ comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
FarmafytBehind Farmafyt are NOSHAQ PARTNERS SCRL, FARMAFYT HEALTHCARE SRL and PHARMBIOSOL SRL. The shares are held by FARMAFYT HEALTHCARE (86.1%) and NOSHAQ (13.5%).
Directors
According to the 2025 annual accounts
Director · represented by ROSA Laurence
Also active at: CAUTION MUTUELLE DES METIERS ET NEGOCES, Fonderies J. Marichal Ketin et Cie, DARDENNE, SOGECOM, VITAVERDE.BIO, HAEMERS Technologies, SPACEBEL, NOSHAQ VENTURE +169 more
Managing director · represented by MIGNON Philippe
Shareholders
86.1%
13.5%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Drève St-Lambert 22 box b
4052 Chaudfontaine
Eigenlostraat 5
9100 Sint-Niklaas
Active since 25 July 2006
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 3 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0882.541.137
- VAT number
- BE 0882.541.137
- Registered office
- Drève St-Lambert 22 bus b, 4052 Chaudfontaine
- Names & denominations
- Farmafyt
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 14 July 2006
- Peppol
- Active · Active since 11 Feb 2026
- Activities · NACE
Groothandel in andere voedingsmiddelen, neg
Handelsbemiddeling in de groothandel in voedings- en genotmiddelen
Handelsbemiddeling in voedings- en genotmiddelen
Overige gespecialiseerde groothandel in voedingswaren